Lung Cancer
Volume 66, Issue 3 , Pages 344-349 , December 2009

Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer

  • Ji-feng Feng

      Affiliations

    • School of Clinical Medical Science, Southeast University, 87 Dingjiaqiao Street, Nanjing 210009, PR China
    • Department of Oncology, Jiangsu Province Cancer Institute and Hospital, Nanjing 210009, PR China
    • ,
  • Jian-zhong Wu

      Affiliations

    • Department of Oncology, Jiangsu Province Cancer Institute and Hospital, Nanjing 210009, PR China
    • ,
  • Sai-nan Hu

      Affiliations

    • Department of Oncology, Jiangsu Province Cancer Institute and Hospital, Nanjing 210009, PR China
    • ,
  • Chang-ming Gao

      Affiliations

    • Department of Oncology, Jiangsu Province Cancer Institute and Hospital, Nanjing 210009, PR China
    • ,
  • Mei-qi Shi

      Affiliations

    • Department of Oncology, Jiangsu Province Cancer Institute and Hospital, Nanjing 210009, PR China
    • ,
  • Zhu-hong Lu

      Affiliations

    • Laboratory of Molecular and Biomolecular Electronics, Southeast University, Nanjing 210006, PR China
    • ,
  • Xin-chen Sun

      Affiliations

    • School of Clinical Medical Science, Southeast University, 87 Dingjiaqiao Street, Nanjing 210009, PR China
    • ,
  • Jin-Rong Zhou

      Affiliations

    • Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    • ,
  • Bao-an Chen

      Affiliations

    • School of Clinical Medical Science, Southeast University, 87 Dingjiaqiao Street, Nanjing 210009, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 25 83272006; fax: +86 25 83272011.

Received 4 December 2008 ,Revised 16 February 2009 ,Accepted 19 February 2009.

References 

  1. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002;38:217–227
  2. Rosell R, Taron M, O’Brate A. Predictive molecular markers in non-small cell lung cancer. Curr Opin Oncol. 2001;13:101–109
  3. Garcia-Campelo R, Alonso-Curbera G, Anton Aparicio LM, Rosell R. Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother. 2005;6:2015–2026
  4. Bepler G, Gautam A, McIntyre LM, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol. 2002;20:1353–1360
  5. Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer. 2005;47:183–192
  6. Kim SO, Jeong JY, Kim MR, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res. 2008;14:3083–3088
  7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  8. Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res. 2006;66:6497–6502
  9. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800–808
  10. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:1878–1885
  11. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17:1818–1825
  12. Souglakos J, Boukovinas I, Taron M, et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer. 2008;98:1710–1715
  13. Smid K, Bergman AM, Eijk PP, et al. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids. 2006;25:1001–1007
  14. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis. 2001;22:593–597
  15. Ronen A, Glickman BW. Human DNA repair genes. Environ Mol Mutagen. 2001;37:241–283
  16. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15:1194–1203
  17. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:2741–2746
  18. Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 2007;39:1318–1328

PII: S0169-5002(09)00113-5

doi: 10.1016/j.lungcan.2009.02.015

Lung Cancer
Volume 66, Issue 3 , Pages 344-349 , December 2009

Article Tools

* Image Usage & Resolution